Prostate Cancer: Abiraterone
Commons · Question 109127 · Tabled 28 Jan 2026 · Department of Health and Social Care · Official record
Answered 3 Feb 2026
Question
Asked by Wendy Morton
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, how many patients with non-metastatic prostate cancer are expected to be eligible for abiraterone in each of the next three financial years; what clinical criteria deter
Answer
Answered by Zubir Ahmed, 3 Feb 2026
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prost...